Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) EBITDA (2020 - 2025)

Historic EBITDA for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to -$38.7 million.

  • Lyell Immunopharma's EBITDA rose 1087.83% to -$38.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$326.2 million, marking a year-over-year decrease of 6145.62%. This contributed to the annual value of -$342.6 million for FY2024, which is 5084.47% down from last year.
  • According to the latest figures from Q3 2025, Lyell Immunopharma's EBITDA is -$38.7 million, which was up 1087.83% from -$42.8 million recorded in Q2 2025.
  • Lyell Immunopharma's EBITDA's 5-year high stood at -$6.0 million during Q4 2022, with a 5-year trough of -$192.4 million in Q4 2024.
  • Moreover, its 5-year median value for EBITDA was -$52.3 million (2025), whereas its average is -$60.2 million.
  • Its EBITDA has fluctuated over the past 5 years, first surged by 9296.3% in 2022, then crashed by 76405.0% in 2023.
  • Quarter analysis of 5 years shows Lyell Immunopharma's EBITDA stood at -$85.3 million in 2021, then skyrocketed by 92.96% to -$6.0 million in 2022, then tumbled by 764.05% to -$51.8 million in 2023, then plummeted by 271.13% to -$192.4 million in 2024, then surged by 79.89% to -$38.7 million in 2025.
  • Its EBITDA stands at -$38.7 million for Q3 2025, versus -$42.8 million for Q2 2025 and -$52.3 million for Q1 2025.